OVERVIEW

HER2-Mutant Non–small lung cancer (NSCLC): Closing the Gap Between Detection and Optimal Treatment is organized by i3 Health.

Dates Available:
February 9, 2026 - February 8, 2027

Statement of Need:
Non–small lung cancer (NSCLC) is a biologically diverse type of lung cancer driven by a wide array of molecular alterations. Human epidermal growth factor receptor 2 (HER2) alterations occur in approximately 4% of patients with NSCLC and include gene mutations, gene amplifications, and protein overexpression. HER2-targeted therapies, including antibody-drug conjugates and tyrosine kinase inhibitors, have shown promising efficacy for patients with limited treatment options. Testing for HER2 alterations is crucial in order to identify patients who may benefit from targeted therapies, and interprofessional collaboration is critical to optimizing timely diagnosis and personalized management throughout the care continuum (Ismail et al, 2025). In this activity, Maria E. Arcila, MD, Attending Physician and Deputy Chief of the Molecular Diagnostics Service in the Department of Pathology and Laboratory Medicine at Memorial Sloan Kettering Cancer Center, and Helena A. Yu, MD, Attending Physician and Thoracic Medical Oncologist at Memorial Sloan Kettering Cancer Center, will explore strategies for closing the gap between detection and optimal treatment in NSCLC with HER2 alterations.

Learning Objectives:
Upon completion of this activity, participants should be able to:

Describe the epidemiology, clinical implications, and diagnostic challenges of HER2-mutant NSCLC
Interpret NGS reports to identify HER2 mutations and integrate this data into treatment planning
Evaluate current and emerging treatment options for HER2-mutant NSCLC
Apply interprofessional strategies to enhance timely diagnosis, testing, and communication across the care continuum for patients with HER2-mutant NSCLC

ACCREDITATION & CREDITS

Jointly Accredited Provider:

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians:
i3 Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates:
i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 2/8/27. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners:
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

1 AMA PRA Category 1 Credit™

1 MOC

1 AAPA

FACULTY

Helena A. Yu

MDInternal Medicine, Medical Oncology

Maria Arcila

MDHematopathology, Molecular Genetic Pathology, Anatomic Pathology & Clinical Pathology

TARGET AUDIENCE

PhysicianPhysician AssistantOncologistsRadiologistsPulmonologistsPathologistsNurse PractitionersThoracic SurgeonsAcademiaAdvanced Practice Providers Other Healthcare Professionals

SPECIALITIES

Oncology

TERMS & CONDITIONS

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME that require everyone in a position to control the content of a CME activity to disclose all financial relationships with ineligible companies that are related to the content of the CME activity. CME activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Maria E. Arcila, MD, discloses that she has served on an advisory board or panel for Biocartis and that she has served as a consultant for AstraZeneca and Biocartis.

Helena A. Yu, MD, discloses that she has served on an advisory board or panel for AbbVie, Amgen, AstraZeneca, Cullinan, Daiichi Sankyo, Janssen, SystImmune, Taiho, and Takeda; and that she has received grants/research support from AstraZeneca, BeOne, Cullinan, Daiichi Sankyo, Janssen, Kumquat, Pfizer, SystImmune, and Taiho.

Linda Ahn, NP, has no relevant financial relationships to disclose.

Katherine D. Gray, MD, has no relevant financial relationships to disclose.

Or Kalchiem-Dekel, MD, has no relevant financial relationships to disclose.

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.

COMMERCIAL SUPPORT
This activity is supported by an independent medical education grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Aggregate participant data will be shared with commercial supporters of this activity.

Contact Information
Technical queries or questions regarding activity credit should be directed to i3 Health at support@emedevents.com.

DISCLAIMER

The information provided at this CME/NCPD activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.